|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ARFIP1 |
Gene summary for ARFIP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ARFIP1 | Gene ID | 27236 |
| Gene name | ADP ribosylation factor interacting protein 1 | |
| Gene Alias | HSU52521 | |
| Cytomap | 4q31.3 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | B4E273 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 27236 | ARFIP1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.06e-21 | -6.84e-01 | 0.0155 |
| 27236 | ARFIP1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 9.23e-06 | -5.73e-01 | -0.1207 |
| 27236 | ARFIP1 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.64e-06 | -4.15e-01 | -0.1464 |
| 27236 | ARFIP1 | HTA11_866_2000001011 | Human | Colorectum | AD | 2.29e-03 | -3.46e-01 | -0.1001 |
| 27236 | ARFIP1 | HTA11_5216_2000001011 | Human | Colorectum | SER | 1.91e-02 | -6.40e-01 | -0.1462 |
| 27236 | ARFIP1 | HTA11_866_3004761011 | Human | Colorectum | AD | 8.48e-16 | -6.04e-01 | 0.096 |
| 27236 | ARFIP1 | HTA11_4255_2000001011 | Human | Colorectum | SER | 2.20e-02 | -5.84e-01 | 0.0446 |
| 27236 | ARFIP1 | HTA11_8622_2000001021 | Human | Colorectum | SER | 7.00e-04 | -6.66e-01 | 0.0528 |
| 27236 | ARFIP1 | HTA11_10711_2000001011 | Human | Colorectum | AD | 8.25e-06 | -5.21e-01 | 0.0338 |
| 27236 | ARFIP1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 3.08e-18 | -5.44e-01 | 0.0674 |
| 27236 | ARFIP1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 3.78e-03 | -3.17e-01 | 0.294 |
| 27236 | ARFIP1 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 6.36e-04 | -3.37e-01 | 0.281 |
| 27236 | ARFIP1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.35e-05 | -3.81e-01 | 0.3859 |
| 27236 | ARFIP1 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 2.23e-05 | -5.57e-01 | 0.2585 |
| 27236 | ARFIP1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 5.43e-26 | -6.83e-01 | 0.3005 |
| 27236 | ARFIP1 | A015-C-203 | Human | Colorectum | FAP | 7.88e-29 | -3.04e-01 | -0.1294 |
| 27236 | ARFIP1 | A015-C-204 | Human | Colorectum | FAP | 7.76e-05 | -2.00e-01 | -0.0228 |
| 27236 | ARFIP1 | A014-C-040 | Human | Colorectum | FAP | 4.96e-03 | -2.65e-01 | -0.1184 |
| 27236 | ARFIP1 | A002-C-201 | Human | Colorectum | FAP | 2.11e-16 | -4.06e-01 | 0.0324 |
| 27236 | ARFIP1 | A002-C-203 | Human | Colorectum | FAP | 3.36e-05 | -3.76e-03 | 0.2786 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003295626 | Oral cavity | EOLP | regulation of actin cytoskeleton organization | 84/2218 | 358/18723 | 4.24e-10 | 3.65e-08 | 84 |
| GO:190290525 | Oral cavity | EOLP | positive regulation of supramolecular fiber organization | 57/2218 | 209/18723 | 8.27e-10 | 6.12e-08 | 57 |
| GO:003227325 | Oral cavity | EOLP | positive regulation of protein polymerization | 42/2218 | 138/18723 | 4.07e-09 | 2.39e-07 | 42 |
| GO:003253523 | Oral cavity | EOLP | regulation of cellular component size | 83/2218 | 383/18723 | 2.73e-08 | 1.12e-06 | 83 |
| GO:011005326 | Oral cavity | EOLP | regulation of actin filament organization | 65/2218 | 278/18723 | 4.55e-08 | 1.72e-06 | 65 |
| GO:005149524 | Oral cavity | EOLP | positive regulation of cytoskeleton organization | 55/2218 | 226/18723 | 1.19e-07 | 3.99e-06 | 55 |
| GO:000815424 | Oral cavity | EOLP | actin polymerization or depolymerization | 53/2218 | 218/18723 | 2.08e-07 | 6.55e-06 | 53 |
| GO:001648223 | Oral cavity | EOLP | cytosolic transport | 44/2218 | 168/18723 | 2.40e-07 | 7.45e-06 | 44 |
| GO:003004123 | Oral cavity | EOLP | actin filament polymerization | 48/2218 | 191/18723 | 2.68e-07 | 8.16e-06 | 48 |
| GO:000806422 | Oral cavity | EOLP | regulation of actin polymerization or depolymerization | 47/2218 | 188/18723 | 4.19e-07 | 1.19e-05 | 47 |
| GO:003083324 | Oral cavity | EOLP | regulation of actin filament polymerization | 44/2218 | 172/18723 | 4.90e-07 | 1.34e-05 | 44 |
| GO:003083222 | Oral cavity | EOLP | regulation of actin filament length | 47/2218 | 189/18723 | 4.95e-07 | 1.34e-05 | 47 |
| GO:003083822 | Oral cavity | EOLP | positive regulation of actin filament polymerization | 26/2218 | 99/18723 | 6.27e-05 | 7.87e-04 | 26 |
| GO:001619722 | Oral cavity | EOLP | endosomal transport | 45/2218 | 230/18723 | 4.63e-04 | 4.07e-03 | 45 |
| GO:00510517 | Oral cavity | EOLP | negative regulation of transport | 80/2218 | 470/18723 | 5.11e-04 | 4.44e-03 | 80 |
| GO:003431422 | Oral cavity | EOLP | Arp2/3 complex-mediated actin nucleation | 12/2218 | 39/18723 | 1.34e-03 | 9.33e-03 | 12 |
| GO:00511255 | Oral cavity | EOLP | regulation of actin nucleation | 10/2218 | 30/18723 | 1.70e-03 | 1.13e-02 | 10 |
| GO:004214722 | Oral cavity | EOLP | retrograde transport, endosome to Golgi | 21/2218 | 91/18723 | 1.89e-03 | 1.21e-02 | 21 |
| GO:004501013 | Oral cavity | EOLP | actin nucleation | 14/2218 | 52/18723 | 2.31e-03 | 1.42e-02 | 14 |
| GO:003238721 | Oral cavity | EOLP | negative regulation of intracellular transport | 15/2218 | 58/18723 | 2.52e-03 | 1.53e-02 | 15 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ARFIP1 | SNV | Missense_Mutation | c.507G>C | p.Lys169Asn | p.K169N | P53367 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| ARFIP1 | SNV | Missense_Mutation | novel | c.76G>A | p.Glu26Lys | p.E26K | P53367 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.98) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ARFIP1 | SNV | Missense_Mutation | novel | c.1097N>G | p.Ala366Gly | p.A366G | P53367 | protein_coding | tolerated(0.3) | benign(0.077) | TCGA-BH-A1FC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ARFIP1 | SNV | Missense_Mutation | rs146931969 | c.1004N>G | p.Asn335Ser | p.N335S | P53367 | protein_coding | tolerated(0.07) | benign(0) | TCGA-FU-A23L-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ARFIP1 | SNV | Missense_Mutation | c.923N>A | p.Arg308His | p.R308H | P53367 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-AA-3975-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| ARFIP1 | SNV | Missense_Mutation | rs776711621 | c.811N>T | p.Arg271Cys | p.R271C | P53367 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| ARFIP1 | SNV | Missense_Mutation | novel | c.1024N>A | p.Ala342Thr | p.A342T | P53367 | protein_coding | tolerated(0.1) | probably_damaging(0.96) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| ARFIP1 | SNV | Missense_Mutation | novel | c.572N>G | p.His191Arg | p.H191R | P53367 | protein_coding | deleterious(0.03) | benign(0.084) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| ARFIP1 | SNV | Missense_Mutation | c.302G>A | p.Gly101Asp | p.G101D | P53367 | protein_coding | tolerated(0.45) | benign(0) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
| ARFIP1 | SNV | Missense_Mutation | c.452N>T | p.Ser151Leu | p.S151L | P53367 | protein_coding | deleterious(0) | possibly_damaging(0.899) | TCGA-D5-6532-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |